N/A N=80 Randomized Double-blind Supportive Care

Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine

Brachial Plexus Anesthesia

Bottom Line

View on ClinicalTrials.gov: NCT02393677 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2015

Primary outcome: Primary: Duration of Analgesia — 413.73; 197.35 minutes

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Ropivacaine (Drug); Ropivacaine with Dexmedetomidine (Drug)
Age: Adult · 18+ yrs
Sex: All
Sponsor: Government Medical College, Haldwani
Primary completion: Jul 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Duration of Analgesia	413.73; 197.35	—
SECONDARY Onset of Sensory Block	—	—
SECONDARY Onset of Motor Block	—	—
SECONDARY Duration of Motor Block	—	—

Summary

80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were included in this prospective study. The patients were randomly assigned to group R (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.

Eligibility Criteria

Inclusion Criteria

80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block.

Exclusion Criteria

Patient refusal
Patients with chronic pain (pain lasting more than 12 weeks)
Those using chronic analgesic medications (opioid, non steroidal anti-inflammatory drugs, anticonvulsants, antidepressants)
Coagulopathy
History of brachial plexus injury
Allergy to the study drugs
Patients taking other medications with α-adrenergic blocking effect
Hepatic or renal insufficiency
Systemic infection or infection at the site of injection, and shoulder surgery.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02393677). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.